Star-tor - Registry For The Evaluation Of The Safety, Tolerability And Efficacy Of Temsirolimus (Torisel), Sunitinib (Sutent), And Axitnib (Inlyta) For The Treatment Of Subjects With Advanced Renal Cell Carcinoma (Mrcc), Mantle Cell Lymphoma (Mcl), And Gastro-intestinal Stroma Tumor (Gist)

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 26 Sep 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axitinib (Primary) ; Sunitinib (Primary) ; Temsirolimus (Primary)
Indications Gastrointestinal stromal tumours; Mantle-cell lymphoma; Renal cell carcinoma
Focus Adverse reactions; Therapeutic Use
Acronyms STAR-TOR
Sponsors Pfizer; Wyeth

Most Recent Events

20 Jun 2022 Status changed from recruiting to completed.
18 Jan 2022 Planned End Date changed from 1 Dec 2023 to 22 Jan 2022.
18 Jan 2022 Planned primary completion date changed from 1 Dec 2023 to 22 Jan 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight